Statins Market to 2018 – Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Publisher Name :
Date: 22-Jan-2013
No. of pages: 60

GBI Research, the leading business intelligence provider, has released its latest research, “Statins Market to 2018 – Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share”, which provides insights into the global statins market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the global statins market for dyslipidemia. The report gives insights into the share of generics in the global statins market for the years 2011 and 2018. The report examines the dyslipidemia treatment usage patterns in the US, the top five countries of Europe (The UK, France, Germany, Spain and Italy), and Japan. In addition to the global market landscape for statins, the report also provides details of the geographical distribution of statins sales in the major markets, including the US, the top five countries of Europe, and Japan. The report also includes insights into the statins R&D product pipeline, and explores the competitive landscape, including major players in the statins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing and co-development deals that have taken place in the statins market.

Statins have dominated the global dyslipidemia therapeutics market for the last few decades. The National Cholesterol Education Program (NECP) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines have recommended the use of statins as the first choice of pharmacotherapy for the treatment of dyslipidemia. The global statins market, valued at $20.5 billion in 2011, is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 7.2% over the next seven years, to reach $12.2 billion by 2018. The highly consolidated statins market is expected to become increasingly competitive in the forecast period, with the patent expiries of (atorvastatin calcium), Vytorin (Ezetimibe/simvastatin), Lescol (fluvastatin) and Crestor (rosuvastatin), followed by severe generic erosion. GBI Research estimates that the generic sector in the global statins market will grow significantly in the future and will pose tough competition to new molecules.

Scope

  • Data and analysis on the statins market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the statins market from 2004 to 2011, with forecasts to 2018.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment-seeking population, diagnosis population and prescription population.
  • Share of generics in the global statins market.
  • Key drivers and restraints that have had a significant impact on the global statins market.
  • The competitive landscape of the global statins market, including top companies benchmarking. The key companies studied in this report are Pfizer, AstraZeneca, Merck and Novartis.
  • Key M&A activities and licensing agreements that took place in the statins market.

Reasons to buy

  • Align their product portfolio to the markets with high growth potential
  • Build effective strategies to launch their pipeline products by identifying potential geographies
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps
  • Develop key strategic initiatives by studying the key strategies of top competitors
  • Devise more tailored country-specific strategies through the understanding of key drivers and barriers and the market potential of each indication for different territories
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious

Statins Market to 2018 – Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Statins Market to 2018 - Introduction 8

3 Statins Market to 2018 - Global Statins Market 9
3.1 Introduction 9
3.2 Global Market Forecast 10
3.2.1 Branded and Generic Market Share 12
3.3 Annual Cost of Treatment 13
3.4 Treatment Usage Patterns 14
3.4.1 Disease Population 15
3.4.2 Treatment Seeking Population 15
3.4.3 Diagnosed Population 15
3.4.4 Prescription Population 15
3.5 Drivers and Restraints to the Statins Market 16
3.5.1 Drivers to the Statins Market 16
3.5.2 Restraints to the Statins Market 17
3.6 Major Marketed Products 19
3.6.1 Crestor (rosuvastatin calcium) 19
3.6.2 Lipitor (atorvastatin calcium) 20
3.6.3 Vytorin (ezetimibe/simvastatin) 21
3.6.4 Zocor (simvastatin) 22
3.6.5 Livalo (pitavastatin calcium) 22
3.6.6 Lescol XL (fluvastatin sodium) 23
3.6.7 Pravachol (pravastatin sodium) 24

4 Statins Market to 2018 - Statins Market in the US 25
4.1 Market 25
4.2 Annual Cost of Therapy (ACT) 27
4.3 Treatment Usage Pattern 28
4.3.1 Diseased Population 29
4.3.2 Treatment Seeking Population 29
4.3.3 Diagnosed Population 29
4.3.4 Patients on Statins Therapy 29

5 Statins Market to 2018 - Statins Market in the Top Five Countries of Europe 30
5.1 Market 30
5.2 Annual Cost of Therapy 33
5.3 Treatment Usage Pattern 34
5.3.1 Diseased Population 35
5.3.2 Treatment Seeking Population 35
5.3.3 Diagnosed Population 35
5.3.4 Patients on Statins Therapy 35

6 Statins Market to 2018 - Statins Market in Japan 36
6.1 Market 36
6.2 Annual Cost of Therapy 38
6.3 Treatment Usage Pattern 40
6.3.1 Diseased Population 41
6.3.2 Treatment Seeking Population 41
6.3.3 Diagnosed Population 41
6.3.4 Patients on Statins Therapy 41

7 Statins Market to 2018 - Product Pipeline Anlaysis 42
7.1 Introduction 42
7.2 Pipeline Analysis 42

8 Statins Market to 2018 - Competitive Landscape 43
8.1 Pfizer Inc. 44
8.1.1 Company Overview 44
8.1.2 SWOT Analysis 44
8.2 AstraZeneca PLC (AstraZeneca) 45
8.2.1 Company Overview 45
8.2.2 SWOT Analysis 45
8.3 Merck & Co Inc 46
8.3.1 Company Overview 46
8.3.2 SWOT Analysis 46
8.4 Novartis AG (Novartis) 47
8.4.1 Company Overview 47
8.4.2 SWOT Analysis 47

9 Statins Market to 2018 - Strategic Consolidation 48
9.1 Merger and Acquisition (M&A) Deals 48
9.2 Licensing Deals 49
9.2.1 Licensing Deals by Geography 49
9.3 Co-development Deals 51

10 Statins Market to 2018 - Appendix 52
10.1 Market Definitions 52
10.2 Abbreviations 52
10.3 Bibliography 55
10.4 Research Methodology 56
10.4.1 Coverage 56
10.4.2 Secondary Research 56
10.4.3 Primary Research 57
10.4.4 Therapeutic Landscape 57
10.4.5 Geographical Landscape 60
10.4.6 Pipeline Analysis 60
10.4.7 Competitive Landscape 60
10.5 Expert Panel Validation 60
10.6 Contact Us 60
10.7 Disclaimer 60

 List of Tables

Table 1: Statins Market, Global, Revenue ($bn), 2004-2011 10
Table 2: Statins Market, Global, Revenue Forecast ($bn), 2011 -2018 10
Table 3: Statins Market, Global, ACT ($), 2004-2011 13
Table 4: Statins Market, Global, ACT ($), 2011-2018 13
Table 5: Statins Market, Global, Treatment Usage Patterns (million), 2004-2011 14
Table 6: Statins Market, Global, Treatment Usage Patterns (million), 2011-2018 14
Table 7: Statins Market, the US, Revenue ($bn), 2004-2011 25
Table 8: Statins Market, the US, Revenue Forecast ($bn), 2011-2018 25
Table 9: Statins Market, the US, ACT ($), 2004-2011 27
Table 10: Statins Market, the US, ACT ($), 2011-2018 27
Table 11: Statins Market, the US, Treatment Usage Pattern (million), 2004-2011 28
Table 12: Statins Market, the US, Treatment Usage Pattern (million), 2011-2018 28
Table 13: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011 31
Table 14: Statins Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018 31
Table 15: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2011 33
Table 16: Statins Market, Top Five Countries of Europe, ACT ($), 2011-2018 33
Table 17: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2011 34
Table 18: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2011-2018 34
Table 19: Statins Market, Japan, Revenue ($bn), 2004-2011 36
Table 20: Statins Market, Japan, Revenue Forecast ($bn), 2011-2018 36
Table 21: Statins Market, Japan, ACT ($), 2004-2011 38
Table 22: Statins Market, Japan, ACT ($), 2011-2018 38
Table 23: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2011 40
Table 24: Statins Market, Japan, Treatment Usage Pattern (million), 2011-2018 40
Table 25: Statins Market, Global, Product Pipeline, 2012 42
Table 26: Statins Market, M&A Deals ($m), 2008-2011 48
Table 27: Statins Market, Licensing Deals, 2005-2011 49
Table 28: Statins Market, Co-Development Deals, 2005-2008 51

 List of Figures

Figure 1: Statins Market, Global, Revenue ($bn), 2004-2018 10
Figure 2: Statins Market, Global, Generic and Branded Market Share (%), 2011 and 2018 12
Figure 3: Statins Market, Global, ACT ($), 2004-2018 13
Figure 4: Statins Market, Global, Treatment Usage Patterns (million), 2004-2018 14
Figure 5: Statins Market, Global, Drivers and Barriers, 2011 16
Figure 6: Statins Market, the US, Revenue ($bn), 2004 -2018 25
Figure 7: Statins Market, the US, ACT ($), 2004-2018 27
Figure 8: Statins Market, the US, Treatment Usage Pattern (million), 2004-2018 28
Figure 9: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2018 31
Figure 10: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2018 33
Figure 11: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2018 34
Figure 12: Statins Market, Japan, Revenue ($bn), 2004-2018 36
Figure 13: Statins Market, Japan, ACT ($), 2004-2018 38
Figure 14: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2018 40
Figure 15: Statins Market, Global, Top Companies' Market Share (%), 2011 43
Figure 16: Statins Market, Pfizer Inc., SWOT Analysis, 2011 44
Figure 17: Statins Market, AstraZeneca, SWOT Analysis, 2011 45
Figure 18: Statins Market, Merck & Co. Inc., SWOT Analysis, 2011 46
Figure 19: Statins Market, Novartis, SWOT Analysis, 2011 47
Figure 20: Statins Market, Strategic Consolidation, 2005-2011 48
Figure 21: GBI Research Market Forecasting Model 59

  • Water Treatment Chemicals Market to be driven by Increasing Demand from Developing Economies
    The global market for water treatment chemicals is growing at a steady pace with rapid urbanization and high demand from end-users. Water treatment chemicals are used for treating municipal water as well as agricultural wastewater. With higher demand for clean, drinking water with increasing population and increase in the number of industries, the global market [...]
  • Rise in Prevalence of Allergic Diseases Driving the Global Allergy Diagnostics Market
    With rise in the incidences of allergic diseases in the world, the global allergy diagnostics market has also witnessed steady growth. In recent years, there has been an increase in the number of people suffering from different allergies, particularly food allergies and drug allergies. The number of people suffering from asthma has also increased in [...]
  • Global Video Surveillance Market Driven by Increasing Demand for Security
    The global market for video surveillance has been witnessing steady growth with increase in demand for advanced surveillance systems by different law enforcement agencies. Increase in adoption of video surveillance by different sectors such as banking and finance, healthcare, transportation, and retail is one of the major drivers in the market. In 2013, the global [...]
  • Global Empty Capsules Market Driven by Growth in Pharmaceutical Industry
    With rapid growth in the pharmaceutical industry, the market for empty capsules has also grown at a steady pace. Some of the factors which are driving the growth of the empty capsules market are rise in aging population which is increasing the demand for capsule based drugs, technological advancement and increase in demand from the [...]
  • Global Aramid Fiber Industry to Witness High Growth in the Future
    With increasing use of aramid fibers in various industries, the global market for aramid fibers has grown significantly in recent years. Aramid fibers have a number of properties such as low density, heat resistance, high tensile strength, abrasion resistance, chemical resistance and impact resistance.  Asia-Pacific is the largest market for aramid fibers, followed by North [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Global and Chinese Clopidogrel Industry, 2009-2019 Market Research Report
    Published: 26-Oct-2014        Price: US $2400 Onwards        Pages: 150
    The 'Global and Chinese Clopidogrel Industry, 2009-2019 Market Research Report' is a professional and in-depth study on the current state of the global Clopidogrel industry with a focus on the Chinese market. The report provides key statistics on the market status of the Clopidogrel manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, ap......
  • Global and Chinese Pravastatin Industry, 2009-2019 Market Research Report
    Published: 26-Oct-2014        Price: US $2400 Onwards        Pages: 150
    The 'Global and Chinese Pravastatin Industry, 2009-2019 Market Research Report' is a professional and in-depth study on the current state of the global Pravastatin industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pravastatin manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, ap......
  • Global and Chinese Dexrazoxane Hydrochloride Industry, 2009-2019 Market Research Report
    Published: 26-Oct-2014        Price: US $2400 Onwards        Pages: 150
    The 'Global and Chinese Dexrazoxane Hydrochloride Industry, 2009-2019 Market Research Report' is a professional and in-depth study on the current state of the global Dexrazoxane Hydrochloride industry with a focus on the Chinese market. The report provides key statistics on the market status of the Dexrazoxane Hydrochloride manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of......
  • Ticagrelor – Comprehensive patent search
    Published: 16-Sep-2014        Price: US $7500 Onwards        
    Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world’s leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won’t need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on......
  • Ticagrelor – Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries)
    Published: 16-Sep-2014        Price: US $1400 Onwards        
    Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know."The most extensive source of patent information available." Product Portfolio Manager - Dr Reddys Laboratories"The database is reliable, frequently updated, well-arranged, user friendly." Dir......
  • Market Research Report on Global and Chinese Clopidogrel Bisulphate Industry, 2009-2019
    Published: 27-Aug-2014        Price: US $2400 Onwards        Pages: 150
    Market Research Report on Global and Chinese Clopidogrel Bisulphate Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Clopidogrel Bisulphate industry. The report firstly reviews the basic information of Clopidogrel Bisulphate including its classification, application and manufacturing technology; The report then explores global and China's top manufacturers of Clopidogrel Bisulphate listing their product specification, capacity, Production value, and market s......
  • Market Research Report on Global and Chinese Fenofibrate (CAS 49562-28-9) Industry, 2009-2019
    Published: 3-Aug-2014        Price: US $2400 Onwards        Pages: 150
    Market Research Report on Global and Chinese Fenofibrate (CAS 49562-28-9) Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Fenofibrate (CAS 49562-28-9) industry. The report firstly reviews the basic information of Fenofibrate (CAS 49562-28-9) including its classification, application and manufacturing technology; The report then explores global and China's top manufacturers of Fenofibrate (CAS 49562-28-9) listing their product specification, capacity, Produc......
  • Market Research Report on Global and Chinese Metolazone (CAS 17560-51-9) Industry, 2009-2019
    Published: 3-Aug-2014        Price: US $2400 Onwards        Pages: 150
    Market Research Report on Global and Chinese Metolazone Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Metolazone industry. The report firstly reviews the basic information of Metolazone including its classification, application and manufacturing technology; The report then explores global and China's top manufacturers of Metolazone listing their product specification, capacity, Production value, and market share etc.; The report further analyzes quant......
  • PharmaPoint: Acute Coronary Syndrome – US Drug Forecast and Market Analysis to 2023
    Published: 31-Jul-2014        Price: US $4995 Onwards        Pages: 233
    GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales (40%) and $7.3bn in generic sales (60%). GlobalData expects that the ACS drug market will grow at a CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn by 2023, of which 64% will be attributed to branded drug sales ($27.7bn) and 36% to generic drug sales ($15.7bn). The current ACS market primarily comprised of antithrombotics, antihyperten......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs